{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:29:12Z","timestamp":1788607752099,"version":"build-2803163510"},"reference-count":49,"publisher":"Portland Press Ltd.","issue":"6","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunopeptidomics is the survey of all peptides displayed on a cell or tissue when bound to human leukocyte antigen (HLA) molecules using tandem mass spectrometry. When attempting to determine the targets of tumour-specific CD8+ T cells, a survey of the potential ligands in tumour tissues is invaluable, and, in comparison with in-silico predictions, provides greater certainty of the existence of individual epitopes, as immunopeptidomics-confirmed CD8+ T-cell epitopes are known to be immunogenic, and direct observation should avoid the risk of autoreactivity which could arise following immunisation with structural homologues. The canonical sources of CD8+ T-cell tumour specific epitopes, such as tumour associated antigens, may be well conserved between patients and tumour types, but are often only weakly immunogenic. Direct observation of tumour-specific neoantigens by immunopeptidomics is rare, although valuable. Thus, there has been increasing interest in the non-canonical origins of tumour-reactive CD8+ T-cell epitopes, such as those arising from proteasomal splicing events, translational\/turnover defects and alternative open reading frame reads. Such epitopes can be identified in silico, although validation is more challenging. Non-self CD8+ T-cell epitopes such as viral epitopes may be useful in certain cancer types with known viral origins, however these have been relatively unexplored with immunopeptidomics to date, possibly due to the paucity of source viral proteins in tumour tissues. This review examines the latest evidence for canonical, non-canonical and non-human CD8+ T-cell epitopes identified by immunopeptidomics, and concludes that the relative contribution for each of these sources to anti-tumour CD8+ T-cell reactivity is currently uncertain.<\/jats:p>","DOI":"10.1042\/ebc20220246","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T08:40:37Z","timestamp":1690533637000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["What do cancer-specific CD8+ T cells see? The contribution of immunopeptidomics"],"prefix":"10.1042","volume":"67","author":[{"given":"Ben","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Centre for Proteomic Research, Biological Sciences and Institute for Life Sciences, Building 85, University of Southampton, SO17 1BJ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1467-9643","authenticated-orcid":false,"given":"Paul","family":"Skipp","sequence":"additional","affiliation":[{"name":"Centre for Proteomic Research, Biological Sciences and Institute for Life Sciences, Building 85, University of Southampton, SO17 1BJ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2023092809011105400_B1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","article-title":"CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness","volume":"47","author":"Ahrends","year":"2017","journal-title":"Immunity"},{"key":"2023092809011105400_B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"2023092809011105400_B3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"2023092809011105400_B4","doi-asserted-by":"publisher","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"2023092809011105400_B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front. Immunol."},{"key":"2023092809011105400_B6","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC class i downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"key":"2023092809011105400_B7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1126\/science.1546328","article-title":"Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry","volume":"255","author":"Hunt","year":"1992","journal-title":"Science"},{"key":"2023092809011105400_B8","doi-asserted-by":"publisher","first-page":"e8503","DOI":"10.15252\/msb.20188503","article-title":"A deep proteome and transcriptome abundance atlas of 29 healthy human tissues","volume":"15","author":"Wang","year":"2019","journal-title":"Mol. Syst. Biol."},{"key":"2023092809011105400_B9","doi-asserted-by":"publisher","first-page":"103768","DOI":"10.1016\/j.isci.2022.103768","article-title":"Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues","volume":"25","author":"Kubiniok","year":"2022","journal-title":"iScience"},{"key":"2023092809011105400_B10","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC Class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J. Immunol."},{"key":"2023092809011105400_B11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol."},{"key":"2023092809011105400_B12","doi-asserted-by":"publisher","first-page":"4032e4031","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"2023092809011105400_B13","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41587-022-01247-9","article-title":"Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens","volume":"40","author":"Weber","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"2023092809011105400_B14","doi-asserted-by":"publisher","first-page":"705974","DOI":"10.3389\/fimmu.2021.705974","article-title":"Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia","volume":"12","author":"Nelde","year":"2021","journal-title":"Front. Immunol."},{"key":"2023092809011105400_B15","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1038\/s41467-020-19464-8","article-title":"Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers","volume":"11","author":"Saini","year":"2020","journal-title":"Nat. Commun."},{"key":"2023092809011105400_B16","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.3390\/cancers13143408","article-title":"Therapeutic cancer vaccination with immunopeptidomics-discovered antigens confers protective antitumor efficacy","volume":"13","author":"Peltonen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2023092809011105400_B17","doi-asserted-by":"publisher","first-page":"818e813","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"2023092809011105400_B18","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat. Commun."},{"key":"2023092809011105400_B19","first-page":"S56","article-title":"Integrating de novo sequencing with sequence database and spectral library search for in-depth analysis of DIA data with PEAKS","volume":"18","author":"Chen","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"2023092809011105400_B20","doi-asserted-by":"publisher","first-page":"9194","DOI":"10.1021\/acs.analchem.0c01545","article-title":"Extending the comprehensiveness of immunopeptidome analyses using isobaric peptide labeling","volume":"92","author":"Pfammatter","year":"2020","journal-title":"Anal. Chem."},{"key":"2023092809011105400_B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jssc.201700919","article-title":"Adding a new separation dimension to MS and LC-MS: What is the utility of ion mobility spectrometry?","volume":"41","author":"D'Atri","year":"2018","journal-title":"J. Sep. Sci."},{"key":"2023092809011105400_B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13073-019-0636-8","article-title":"Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma","volume":"11","author":"Loffler","year":"2019","journal-title":"Genome Med."},{"key":"2023092809011105400_B23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s43018-021-00226-4","article-title":"Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity","volume":"2","author":"Manczinger","year":"2021","journal-title":"Nat. Cancer"},{"key":"2023092809011105400_B24","doi-asserted-by":"publisher","first-page":"100143","DOI":"10.1016\/j.mcpro.2021.100143","article-title":"Immunopeptidogenomics: Harnessing RNA-Seq to Illuminate the Dark Immunopeptidome","volume":"20","author":"Scull","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"2023092809011105400_B25","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41467-020-14968-9","article-title":"Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes","volume":"11","author":"Chong","year":"2020","journal-title":"Nat. Commun."},{"key":"2023092809011105400_B26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nmeth.4631","article-title":"Improved Ribo-seq enables identification of cryptic translation events","volume":"15","author":"Erhard","year":"2018","journal-title":"Nat. Methods"},{"key":"2023092809011105400_B27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","article-title":"Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer","volume":"40","author":"Ouspenskaia","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"2023092809011105400_B28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nmeth.3688","article-title":"Detecting actively translated open reading frames in ribosome profiling data","volume":"13","author":"Calviello","year":"2016","journal-title":"Nat. Methods"},{"key":"2023092809011105400_B29","doi-asserted-by":"publisher","first-page":"108815","DOI":"10.1016\/j.celrep.2021.108815","article-title":"Most non-canonical proteins uniquely populate the proteome or immunopeptidome","volume":"34","author":"Ruiz Cuevas","year":"2021","journal-title":"Cell Rep."},{"key":"2023092809011105400_B30","doi-asserted-by":"publisher","first-page":"100228","DOI":"10.1016\/j.mcpro.2022.100228","article-title":"Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability","volume":"21","author":"Cleyle","year":"2022","journal-title":"Mol. Cell. Proteomics"},{"key":"2023092809011105400_B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2023092809011105400_B32","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1038\/s41467-021-23713-9","article-title":"Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics","volume":"12","author":"Wilhelm","year":"2021","journal-title":"Nat. Commun."},{"key":"2023092809011105400_B33","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41467-022-34904-3","article-title":"AlphaPeptDeep: a modular deep learning framework to predict peptide properties for proteomics","volume":"13","author":"Zeng","year":"2022","journal-title":"Nat. Commun."},{"key":"2023092809011105400_B34","doi-asserted-by":"publisher","first-page":"8247","DOI":"10.1073\/pnas.1705691114","article-title":"De novo peptide sequencing by deep learning","volume":"114","author":"Tran","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2023092809011105400_B35","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","article-title":"Identification of the cryptic HLA-I immunopeptidome","volume":"8","author":"Erhard","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"2023092809011105400_B36","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1074\/mcp.RA118.000877","article-title":"Estimating the contribution of proteasomal spliced peptides to the HLA-I ligandome","volume":"17","author":"Mylonas","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"2023092809011105400_B37","doi-asserted-by":"publisher","first-page":"100099","DOI":"10.1016\/j.mcpro.2021.100099","article-title":"Are there indeed spliced peptides in the immunopeptidome?","volume":"20","author":"Admon","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"2023092809011105400_B38","doi-asserted-by":"publisher","first-page":"645770","DOI":"10.3389\/fimmu.2021.645770","article-title":"IFNgamma Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation","volume":"12","author":"Goncalves","year":"2021","journal-title":"Front. Immunol."},{"key":"2023092809011105400_B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s40425-019-0769-8","article-title":"Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment","volume":"7","author":"Newey","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"key":"2023092809011105400_B40","doi-asserted-by":"publisher","first-page":"2154115","DOI":"10.1080\/2162402X.2022.2154115","article-title":"Cellular senescence enhances adaptive anticancer immunosurveillance","volume":"12","author":"Marin","year":"2023","journal-title":"Oncoimmunology"},{"key":"2023092809011105400_B41","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1182\/bloodadvances.2021006069","article-title":"Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment","volume":"6","author":"Bourne","year":"2022","journal-title":"Blood Adv."},{"key":"2023092809011105400_B42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41587-022-01464-2","article-title":"Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors","volume":"41","author":"Kacen","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"2023092809011105400_B43","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1101\/gr.248922.119","article-title":"LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly","volume":"29","author":"Attig","year":"2019","journal-title":"Genome Res."},{"key":"2023092809011105400_B44","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/0008-5472.CAN-15-3139","article-title":"Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer","volume":"76","author":"Cherkasova","year":"2016","journal-title":"Cancer Res."},{"key":"2023092809011105400_B45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.omto.2018.12.010","article-title":"Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma","volume":"12","author":"Rajaraman","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"2023092809011105400_B46","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41467-021-22115-1","article-title":"Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy","volume":"12","author":"Kottke","year":"2021","journal-title":"Nat. Commun."},{"key":"2023092809011105400_B47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"2023092809011105400_B48","doi-asserted-by":"publisher","first-page":"e003572","DOI":"10.1136\/jitc-2021-003572","article-title":"Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens","volume":"10","author":"Bekri","year":"2022","journal-title":"J. Immunotherapy Cancer"},{"key":"2023092809011105400_B49","doi-asserted-by":"publisher","first-page":"102172","DOI":"10.1016\/j.coi.2022.102172","article-title":"Chasing neoantigens; invite naive T cells to the party","volume":"75","author":"Bollineni","year":"2022","journal-title":"Curr. Opin. Immunol."}],"container-title":["Essays in Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/67\/6\/957\/950393\/ebc-2022-0246c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/67\/6\/957\/950393\/ebc-2022-0246c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:01:22Z","timestamp":1695891682000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article\/67\/6\/957\/233325\/What-do-cancer-specific-CD8-T-cells-see-The"}},"subtitle":[],"editor":[{"given":"Cathy","family":"Tournier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Awen","family":"Gallimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2023,9,28]]}},"URL":"https:\/\/doi.org\/10.1042\/ebc20220246","relation":{},"ISSN":["0071-1365","1744-1358"],"issn-type":[{"value":"0071-1365","type":"print"},{"value":"1744-1358","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,9]]}}}